10 C
New Delhi
January 25, 2021
PowerNews TV
Health

Russia ties up with Dr. Reddy’s Lab for phase-3 trials of Sputnik V vaccine

Dr. Reddy’s Laboratory sputnik V

Indian pharma company Dr. Reddy’s Laboratory Ltd. has entered into a collaboration with the Russian Direct Investment Fund (RDIF) to conduct phase-III trial of Russian vaccine Sputnik V. It has also been decided that they will distribute 10 crore doses of the COVID-19 vaccine.

A week earlier the Indian government announced a discussion with the Russian government about manufacturing the Russian vaccine in India and conducting Phase-III clinical trials of the same.

On the other hand, two other Indian pharma companies are tying up with foreign vaccine developers— Oxford-AstraZeneca and Janssen Pharmaceutica NV (“Janssen”) to mass-produce the vaccine candidates and conduct phase III trials in India. They are the Pune-based Serum Institute of India and Hyderabad-based Biological-E.

Russia had approved the emergency registration of Sputnik V last month. The federal government’s approval of the vaccine much before the critical phase III trials was severely criticized by scientists from around the world. The vaccine has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Moscow.

In a statement, Dr. Reddy’s Lab co-chairman and managing director GV Prasad said, “We are pleased to partner with RDIF to bring the vaccine to India. Phase I and II results have shown promise, and we will be conducting phase-III trials in India to meet the requirements of Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India.”

However, the vaccine will have to go through the rigorous phase III trials in India before approving it for human use. It has to be ascertained that it is safe and effective before being approved by domestic regulators. The collaboration between Dr. Reddy’s and RDIF is an indication of this.  Head of the National Covid-19 Task Force, Dr. VK Paul had said last week that there would be phase-III trial in the normal course of things. As per the requirements of science and domestic regulations, the government is also facilitating the conduct of the trials.

Related posts

COVID-19 vaccine may be ready by December: Adar Poonawala

POWER NEWS TEAM

Covaxin, Bharat Biotech’sCOVID-19 vaccine to conduct Phase-3 Trials in Lucknow, Gorakhpur

POWER NEWS TEAM

Indian companies may procure Covid-19 vaccines for its employees

POWER NEWS TEAM

Leave a Comment